IDT Expands Oligonucleotide Manufacturing in Singapore
News Dec 02, 2015
Integrated DNA Technologies (“IDT”), the global leader in custom nucleic acid synthesis, has entered into a definitive agreement to acquire the oligonucleotide synthesis business of AITbiotech Pte. Ltd. in Singapore (“AITbiotech”). With this acquisition, IDT expands its customer base across Southeast Asia making it possible for these additional customers to now have access to its broad range of products for genomic applications. AITbiotech will continue operations in its other core business areas.
Dr. Joseph A. Walder, IDT founder and chief executive officer, commented, “With this purchase, we further expand our presence in the region and look forward to welcoming AITbiotech customers to IDT. The entire Singapore scientific research market can now benefit from IDT’s unrivalled manufacturing capabilities, design expertise and fast turnaround times.”
Alex Thian, chief executive officer of AITbiotech, added, “We share a commitment with IDT to produce consistently high-quality oligos and to provide personal service for customers. Both companies are working diligently to facilitate a smooth transition of the business and we are excited to begin this next chapter in the ever expanding Singapore market.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.